Nerve pain has human cannabis trials behind it, and they are more tempered than the headlines suggest, and the terpene evidence underneath is thinner still. You deserve both facts in that order.
What patients are managing
Neuropathic pain qualifies in Pennsylvania under neuropathies and under severe chronic or intractable pain of neuropathic origin. It is its own kind of pain, the burning, electric, pins-and-needles pain of a nerve that has been injured or is misfiring, and it often responds differently from ordinary pain. Cannabis is a common thing to try for it, and the evidence is real but should be read carefully.
What the research supports: cannabinoids
The 2018 Cochrane review of cannabis-based medicines for chronic neuropathic pain found low-to-moderate-quality evidence of a small benefit, a somewhat better chance of meaningful pain reduction than placebo, set against frequent nervous-system and psychiatric side effects. The reviewers concluded the potential benefits may be outweighed by the harms. The larger National Academies report folded neuropathic pain into its broader chronic-pain conclusion, but the condition-specific picture is the more cautious one.
What the research supports: terpenes
As with all pain, the terpene evidence is animal. Beta-caryophyllene suppressed nerve-injury and antiretroviral-induced neuropathic pain in mice through the CB2 receptor. Myrcene showed antinociceptive effects in a mouse nerve-injury model, and terpene blends eased neuropathic pain in mice through adenosine receptors. No individual terpene has a human neuropathic-pain trial.
What the research does not support
No terpene has been shown to relieve nerve pain in a human under trial conditions, and even the cannabinoid evidence here is weaker and more contested than for general pain, with Cochrane warning the harms may outweigh the benefit. A terpene profile is not a proven driver of neuropathic relief. Beta-caryophyllene and myrcene have a real mechanism and decent animal support, which is a reason to pay attention, not a reason to expect a result.
How Terpenology scores this
Terpenology shows a nerve-pain Fit score at low-to-moderate confidence and says so on the card. The score reads the printed terpene percentages, weighs them against what the literature supports, and caps itself when the panel is incomplete or the evidence is animal-tier. It is built to tell you when a product is a poor match, which on a contested condition like this one is the honest and useful thing to do.
Terpenes worth reading about
Terpenology is educational, not medical advice. Terpene effects are tendencies commonly reported by patients and early research, never guaranteed outcomes. Nothing here is a substitute for the care of your certifying physician, your pharmacist, or the specialist treating your condition.